Greater Asia News
Takeda Announces Voluntary Withdrawal of U.S. Biologics License Application (BLA) for Dengue Vaccine Candidate TAK-003
Takeda (TSE:4502/NYSE:TAK) today announced that the Company has voluntarily withdrawn the U.S. Biologics License Application (BLA) for its dengue vaccine candidate, TAK-003, following discussions with the U.S. Food and Drug Administration (FDA) on aspects of data collection, which cannot be addressed within the current BLA review cycle.
BIORCHESTRA Wins Grand Prize in 2023 Merck Advance Biotech Grant Program
BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System (CNS), today announced receipt of the grand prize award in the 2023 Merck Advance Biotech Grant Program.
Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer’s Disease Test
Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases.
Santen Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North America
Santen Pharmaceutical Co., Ltd. (hereafter Santen) announced today that it has signed licensing agreements and an asset transfer agreement with two U.S. companies.
Neurophet to unveil brain image analysis technology related to treatment of Alzheimer’s disease at AAIC 2023
Neurophet, an artificial intelligence (AI) solution company for brain disease, announced its participation in the Alzheimer's Association International Conference (AAIC) 2023, which is held in Amsterdam, Netherlands.
SK Biopharmaceuticals Makes Big Bets to be ‘Big Biotech’
SK Biopharmaceuticals' Chief Executive Officer Donghoon Lee presented the new vision at a press conference in Seoul, Tuesday, introducing its plan to globalize and mobilize its therapeutic modalities and platforms of radiopharmaceutical therapy (RPT)[1] and targeted protein degradation (TPD)[2].
Ginkgo Bioworks and Sumitomo Chemical Announce Expanded Partnership To Develop Functional Chemicals with Synthetic Biology
Sumitomo Chemical Co., Ltd (TSE:4005), one of Japan's leading chemical companies, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new program to develop functional chemicals with synthetic biology and expand upon the companies' existing biomanufacturing partnership.
Astellas and Eko Health Announce Agreement to Incorporate Next Generation Eko CORE 500™ Digital Stethoscope into Z1608, an Innovative Solution Under Development for Heart Failure Patients Built on Welldoc’s Proven Digital Therapeutic Platform
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Eko Health Inc. (Co-Founder and CEO: Connor Landgraf, "Eko") announced today that they have entered into a License & Supply Agreement for the global supply and license of Eko's latest digital stethoscope, the CORE 500™, and a custom suite of Eko's AI-powered cardiovascular disease detection software.
EMA Accepts MAA for DMB-3115 of Dong-A ST, a Stelara Biosimilar
Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced on July 14 that the European Medicine Agency (EMA) confirmed acceptance of Marketing Authorization Application (MAA) for DMB-3115, a biosimilar of Stelara® (Ustekinumab).
CBC Group Appoints Billy Cho as Senior Managing Director, Private Equity and Co-Head, Joint Value Creation
CBC Group (“CBC”), Asia’s largest healthcare-dedicated investment firm headquartered in Singapore, today announced the appointment of Billy Cho as Senior Managing Director, Private Equity and Co-Head, Joint Value Creation.
